MansiR.ShahMD(She/Her)
Oncology • New Brunswick, NJHematologic Oncology
Assistant Professor of Medicine
Dr. Shah is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
125 Paterson St
Ste 5200
New Brunswick, NJ 08901Phone+1 732-235-7223
Summary
- Dr. Mansi Shah, based in New Brunswick, NJ, is an Oncologist specializing in Hematologic Oncology. She completed her fellowship in Hematology and Medical Oncology in 2020 from Rutgers Health/Robert Wood Johnson Medical School, where she is currently an Assistant Professor. Her experience includes immunotherapy, multiple myeloma, hematologic malignancies, autologous stem cell transplantation, and car-t. She has several publications to her name in reputable medical journals. Shah is also involved in clinical trials, notably a Phase 1/2 Study of REGN5458 in adult patients with relapsed or refractory multiple myeloma.
Education & Training
Rutgers Health/Robert Wood Johnson Medical SchoolFellowship, Hematology and Medical Oncology, 2020
Sidney Kimmel Medical College at Thomas Jefferson University/TJUHResidency, Internal Medicine, 2017
Rutgers Robert Wood Johnson Medical SchoolClass of 2014
Certifications & Licensure
NJ State Medical License 2017 - 2025
PA State Medical License 2004 - 2017- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Phase 1/2 Study of REGN5458 in Adult Patients With Relapsed or Refractory Multiple Myeloma Start of enrollment: 2019 Jan 23
Roles: Contact
- Loratadine for the Reduction of G-CSF Induced Bone Pain in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization Start of enrollment: 2022 Apr 18
Publications & Presentations
PubMed
- Immune prognostic score predicts the risk of infection and survival outcomes in patients with relapsed multiple myeloma treated with bispecific antibodies.Othman Salim Akhtar, Aniko Szabo, Vineel Bhatlapenumarthi, Mark Forsberg, Metodi Balev
British Journal of Haematology. 2024-11-01 - Disparities in PI3K/mTOR inhibitor use, toxicities, and outcomes among patients with metastatic breast cancer.Claire Sathe, Melissa K Accordino, David DeStephano, Mansi Shah, Jason D Wright
Breast Cancer Research and Treatment. 2024-08-01 - 5 citationsLinvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma.Naresh Bumma, Joshua Richter, Sundar Jagannath, Hans C Lee, James E Hoffman
Journal of Clinical Oncology. 2024-08-01
Abstracts/Posters
- Narcotic Use in Multiple Myeloma Patients at the Time of ASCT and One-Year Follow upMansi Shah, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Outcome of Autologous Stem Cell Transplantation Following PD-(L)1 Based Salvage Therapy for Multiply Relapsed Patients with Classic Hodgkin LymphomaMansi Shah, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Press Mentions
Multiple Myeloma Gets New Attention After Patti Scialfa, Bruce Springsteen's Wife and Bandmate, Reveals DiagnosisSeptember 10th, 2024- Multiple Myeloma: More Common Than You ThinkMarch 1st, 2022
Professional Memberships
- Member
- Member
- Member
- International Myeloma SocietyMember
Other Languages
- Hindi, Gujarati, Spanish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
